藏药郎庆阿塔治疗肝纤维化的实验研究  

Experimental Study on the Therapeutical Effect of Lang Qing A Ta on Hepatic Fibrosis

作　　者：彭蕴茹[1] 丁永芳[1] 罗宇慧[1] 黄一平[1] 

机构地区：[1]江苏省中医药研究院,南京210028

出　　处：《中国实验方剂学杂志》2012年第11期189-194,共6页Chinese Journal of Experimental Traditional Medical Formulae

摘　　要：目的:研究藏药郎庆阿塔对复合因素所致大鼠肝纤维化的治疗作用。方法:清洁级Wistar大鼠90只采用复合因素(高脂低蛋白饲料喂养、含乙醇饮用水加皮下注射四氯化碳)制备大鼠肝纤维化模型,造模6周末随机处死12只造模大鼠,通过肝组织病理检查及血清肝功能指标来检查肝纤维化模型成功率。将模型大鼠随机分为模型对照组、阳性药复方鳖甲软肝片组(0.55 g.kg-1)、郎庆阿塔颗粒给药高、中、低剂量组(生药11.4,5.7,2.85 g.kg-1),另设正常对照组。各组大鼠于分组后即日(第7周)开始ig给药,每日1次,连续ig给药7周。治疗结束后,检测血清中生化指标和肝纤维化指标,并取肝脏组织,测定肝脏组织中羟脯氨酸含量、超氧化物歧化酶(SOD)活力及丙二醛(MDA)水平,另取肝脏组织标本进行病理组织学检查。结果:郎庆阿塔能明显降低肝纤维化大鼠增高的肝脏系数和肝组织中羟脯氨酸含量(P<0.05～P<0.01),显著降低肝纤维化大鼠血清中异常升高的天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、碱性磷酸酶(ALP)、总胆红素(T-BIL)、透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原氨端肽(PⅢNP)及Ⅳ型胶原(CⅣ)(P<0.05～P<0.01),升高白蛋白(ALB)和A/G比值,能明显升高肝组织中SOD活力(P<0.05～P<0.01)、降低异常升高的MDA水平(P<0.05～P<0.01),病理组织学检查结果表明郎庆阿塔高、中剂量对肝纤维化大鼠肝纤维组织增生、肝组织炎症活动度均有显著的改善作用(P<0.05～P<0.01),并能显著降低肝组织中胶原纤维面积(P<0.05～P<0.01)。结论:藏药郎庆阿塔具有明显的治疗肝纤维化作用。Objective： To study the therapeutical effect of Lang Qing A Ta （LQAT） on hepatic fibrosis induced by composite factors in rats. Method： The hepatic fibrosis model was induced by high fat and low protein feed combined with administration of ethyl alcohol and a subcutaneous injection of CC14in rats and the model rats were divided into five groups as model group, Fufang Biejia Ruangan table group and LQAT groups at three doses. The rats were orally treated with corresponding decoctions once a day for 7 weeks. The levels of biochemical indicators and hepatic fibrosis indicators in serum were detected, as well as the levels of hydroxyproline, superoxide dismutaso （SOD） and malondialdehyde （MDA） in liver. The histopathologic examination was proceeded to evaluate the pathological changes in livers. Result： LQAT decoction could remarkably decrease the liver coefficients and hydroxyproline contents of liver in hepatic fibrosis rats, decrease the levels of aspartate aminotransferase （AST） , alanine aminotransferase （ALT） , alkalinephosphatase （ALP） , total bilirubin （ T- BIL）, hyaluronic acid （HA）, laminin （LN）, procollagen ]II N-terminal peptide （PI]I NP）, collagen type IV （C IV） and increase the levels of albumin （ALB） and alburmin/globulin （A/G） in serum. Furthermore, LQAT decoction could obviously increase the activity of SOD and decrease the MDA levels in liver. The results of histopathologic examination showed that LQAT at high and medium doses could ameliorate the pathological changes such as fibroplasia and inflammation and decrease the area of collagen fiber in livers. Conclusion： LQAT decoction has significant therapeutical effects on hepatic fibrosis in rats.

关 键 词：藏药 郎庆阿塔 肝纤维化 

分 类 号：R285.5[医药卫生—中药学]